NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637113. A total of 32 filers reported holding NABRIVA THERAPEUTICS PLC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $8,000 | -57.9% | 43,728 | -2.7% | 0.01% | -50.0% |
| Q1 2022 | $19,000 | -17.4% | 44,951 | +17.1% | 0.01% | -14.3% |
| Q4 2021 | $23,000 | -57.4% | 38,386 | -16.2% | 0.01% | -60.0% |
| Q3 2021 | $54,000 | -10.0% | 45,784 | +3.6% | 0.04% | -14.6% |
| Q2 2021 | $60,000 | -20.0% | 44,196 | -1.9% | 0.04% | -25.5% |
| Q1 2021 | $75,000 | -26.5% | 45,033 | +6.4% | 0.06% | -32.1% |
| Q4 2020 | $102,000 | – | 42,308 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABG Innovation Capital Partners III GP Ltd | 45,849 | $8,000 | 0.60% |
| Aisling Capital Management LP | 90,000 | $16,000 | 0.01% |
| Frazier Life Sciences Management, L.P. | 425,650 | $77,000 | 0.01% |
| Values First Advisors, Inc. | 43,728 | $8,000 | 0.01% |
| Virtu Financial LLC | 127,585 | $23,000 | 0.00% |
| CCG WEALTH MANAGEMENT, LLC | 10,000 | $2,000 | 0.00% |
| Running Point Capital Advisors, LLC | 10,000 | $2,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 125 | $0 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 42,738 | $7,000 | 0.00% |